{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T03:21:04Z","timestamp":1790997664223,"version":"4.1.0"},"reference-count":72,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,1,14]],"date-time":"2020-01-14T00:00:00Z","timestamp":1578960000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012351","name":"Mitsubishi Tanabe Pharma Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012351","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","award":["R3500-AD-1805"],"award-info":[{"award-number":["R3500-AD-1805"]}],"id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004095","name":"Kyowa Hakko Kirin","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004095","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Allergology International"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1016\/j.alit.2020.01.002","type":"journal-article","created":{"date-parts":[[2020,1,30]],"date-time":"2020-01-30T03:17:07Z","timestamp":1580354227000},"page":"187-196","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":94,"title":["Dupilumab: Basic aspects and applications to allergic diseases"],"prefix":"10.1016","volume":"69","author":[{"given":"Kazuto","family":"Matsunaga","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norito","family":"Katoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeharu","family":"Fujieda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Izuhara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiji","family":"Oishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.alit.2020.01.002_bib1","series-title":"Inflammation and Allergy Drug Design","first-page":"175","article-title":"Interleukin 4, interleukin 13, and interleukin 9","author":"Izuhara","year":"2011"},{"key":"10.1016\/j.alit.2020.01.002_bib2","doi-asserted-by":"crossref","first-page":"263","DOI":"10.2174\/1568010023344661","article-title":"IL-4 and IL-13: their pathological roles in allergic diseases and their potential in developing new therapies","volume":"1","author":"Izuhara","year":"2002","journal-title":"Curr Drug Targets Inflamm Allergy"},{"key":"10.1016\/j.alit.2020.01.002_bib3","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.2147\/TCRM.S125964","article-title":"Dupilumab in the management of moderate-to-severe asthma: the data so far","volume":"13","author":"Barranco","year":"2017","journal-title":"Ther Clin Risk Manag"},{"key":"10.1016\/j.alit.2020.01.002_bib4","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.alit.2015.03.004","article-title":"Group 2 innate lymphoid cells and asthma","volume":"64","author":"Kabata","year":"2015","journal-title":"Allergol Int"},{"key":"10.1016\/j.alit.2020.01.002_bib5","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.alit.2017.04.006","article-title":"T\u00a0follicular helper and TH2 cells in allergic responses","volume":"66","author":"Kubo","year":"2017","journal-title":"Allergol Int"},{"key":"10.1016\/j.alit.2020.01.002_bib6","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1111\/all.13814","article-title":"Periostin: an emerging biomarker for allergic diseases","volume":"74","author":"Izuhara","year":"2019","journal-title":"Allergy"},{"key":"10.1016\/j.alit.2020.01.002_bib7","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1042\/BST0370873","article-title":"Cytoplasmic tail of IL-13R\u03b12 regulates IL-4 signal transduction","volume":"37","author":"Andrews","year":"2009","journal-title":"Biochem Soc Trans"},{"key":"10.1016\/j.alit.2020.01.002_bib8","doi-asserted-by":"crossref","first-page":"740","DOI":"10.2174\/156652409788970652","article-title":"The signaling function of the IL-13R\u03b12 receptor in the development of gastrointestinal fibrosis and cancer surveillance","volume":"9","author":"Strober","year":"2009","journal-title":"Curr Mol Med"},{"key":"10.1016\/j.alit.2020.01.002_bib9","doi-asserted-by":"crossref","first-page":"123","DOI":"10.2147\/JAA.S52387","article-title":"Dupilumab: a novel treatment for asthma","volume":"7","author":"Vatrella","year":"2014","journal-title":"J\u00a0Asthma Allergy"},{"key":"10.1016\/j.alit.2020.01.002_bib10","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1165\/ajrcmb.12.3.7873190","article-title":"Allergen-induced airway inflammation and bronchial responsiveness in wild-type and interleukin-4-deficient mice","volume":"12","author":"Brusselle","year":"1995","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1016\/j.alit.2020.01.002_bib11","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1172\/JCI119292","article-title":"Aeroallergen-induced eosinophilic inflammation, lung damage, and airways hyperreactivity in mice can occur independently of IL-4 and allergen-specific immunoglobulins","volume":"99","author":"Hogan","year":"1997","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.alit.2020.01.002_bib12","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.4049\/jimmunol.161.3.1501","article-title":"A\u00a0novel T cell-regulated mechanism modulating allergen-induced airways hyperreactivity in BALB\/c mice independently of IL-4 and IL-5","volume":"161","author":"Hogan","year":"1998","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.alit.2020.01.002_bib13","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1084\/jem.183.1.109","article-title":"Interleukin 4, but not interleukin 5 or eosinophils, is required in a murine model of acute airway hyperreactivity","volume":"183","author":"Corry","year":"1996","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.alit.2020.01.002_bib14","doi-asserted-by":"crossref","first-page":"108","DOI":"10.4049\/jimmunol.165.1.108","article-title":"Integrated signals between IL-13, IL-4, and IL-5 regulate airways hyperreactivity","volume":"165","author":"Webb","year":"2000","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.alit.2020.01.002_bib15","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1126\/science.282.5397.2261","article-title":"Requirement for IL-13 independently of IL-4 in experimental asthma","volume":"282","author":"Gr\u00fcnig","year":"1998","journal-title":"Science"},{"key":"10.1016\/j.alit.2020.01.002_bib16","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1084\/jem.187.9.1537","article-title":"Abrogation of bronchial eosinophilic inflammation and airway hyperreactivity in signal transducers and activators of transcription (STAT)6-deficient mice","volume":"187","author":"Akimoto","year":"1998","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.alit.2020.01.002_bib17","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1164\/ajrccm.160.4.9809065","article-title":"The failure of STAT6-deficient mice to develop airway eosinophilia and airway hyperresponsiveness is overcome by interleukin-5","volume":"160","author":"Tomkinson","year":"1999","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.alit.2020.01.002_bib18","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1165\/ajrcmb.26.2.4600","article-title":"The Th2 lymphocyte products IL-4 and IL-13 rapidly induce airway hyperresponsiveness through direct effects on resident airway cells","volume":"26","author":"Venkayya","year":"2002","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1016\/j.alit.2020.01.002_bib19","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1126\/science.282.5397.2258","article-title":"Interleukin-13: central mediator of allergic asthma","volume":"282","author":"Wills-Karp","year":"1998","journal-title":"Science"},{"key":"10.1016\/j.alit.2020.01.002_bib20","doi-asserted-by":"crossref","first-page":"5219","DOI":"10.4049\/jimmunol.166.8.5219","article-title":"Therapeutic effect of IL-13 immunoneutralization during chronic experimental fungal asthma","volume":"166","author":"Blease","year":"2001","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.alit.2020.01.002_bib21","doi-asserted-by":"crossref","first-page":"4668","DOI":"10.4049\/jimmunol.167.8.4668","article-title":"Critical role for IL-13 in the development of allergen-induced airway hyperreactivity","volume":"167","author":"Walter","year":"2001","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.alit.2020.01.002_bib22","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1046\/j.0022-202x.2001.01484.x","article-title":"Expression of interleukin-4 in the epidermis of transgenic mice results in a pruritic inflammatory skin disease: an experimental animal model to study atopic dermatitis","volume":"117","author":"Chan","year":"2001","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.alit.2020.01.002_bib23","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1111\/j.1365-2249.2004.02649.x","article-title":"Early up-regulation of Th2 cytokines and late surge of Th1 cytokines in an atopic dermatitis model","volume":"138","author":"Chen","year":"2004","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.alit.2020.01.002_bib24","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1038\/jid.2008.295","article-title":"Transgenic expression of interleukin-13 in the skin induces a pruritic dermatitis and skin remodeling","volume":"129","author":"Zheng","year":"2009","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.alit.2020.01.002_bib25","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1172\/JCI5669","article-title":"Roles of TH1 and TH2 cytokines in a murine model of allergic dermatitis","volume":"103","author":"Spergel","year":"1999","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.alit.2020.01.002_bib26","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1111\/1346-8138.15090","article-title":"Clinical practice guidelines for the management of atopic dermatitis 2018","volume":"46","author":"Katoh","year":"2019","journal-title":"J\u00a0Dermatol"},{"key":"10.1016\/j.alit.2020.01.002_bib27","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1111\/j.1346-8138.2006.00187.x","article-title":"Prevalence of atopic dermatitis determined by clinical examination in Japanese adults","volume":"33","author":"Saeki","year":"2006","journal-title":"J\u00a0Dermatol"},{"key":"10.1016\/j.alit.2020.01.002_bib28","doi-asserted-by":"crossref","first-page":"406","DOI":"10.2500\/aap.2018.39.4175","article-title":"The burden of atopic dermatitis","volume":"39","author":"Reed","year":"2018","journal-title":"Allergy Asthma Proc"},{"key":"10.1016\/j.alit.2020.01.002_bib29","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.jaad.2019.03.037","article-title":"Burden of illness in adults with atopic dermatitis: analysis of national health and wellness survey data from France, Germany, Italy, Spain, and the United Kingdom","volume":"81","author":"Eckert","year":"2019","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.alit.2020.01.002_bib30","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.jaad.2015.10.043","article-title":"Patient burden of moderate to severe atopic dermatitis (AD): insights from a phase 2b clinical trial of dupilumab in adults","volume":"74","author":"Simpson","year":"2016","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.alit.2020.01.002_bib31","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.alit.2016.12.002","article-title":"Atopic dermatitis: immune deviation, barrier dysfunction, IgE autoreactivity and new therapies","volume":"66","author":"Furue","year":"2017","journal-title":"Allergol Int"},{"key":"10.1016\/j.alit.2020.01.002_bib32","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.jaci.2014.06.014","article-title":"Causes of epidermal filaggrin reduction and their role in the pathogenesis of atopic dermatitis","volume":"134","author":"Thyssen","year":"2014","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.alit.2020.01.002_bib33","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jdermsci.2012.07.004","article-title":"Th1 cytokines accentuate but Th2 cytokines attenuate ceramide production in the stratum corneum of human epidermal equivalents: an implication for the disrupted barrier mechanism in atopic dermatitis","volume":"68","author":"Sawada","year":"2012","journal-title":"J\u00a0Dermatol Sci"},{"key":"10.1016\/j.alit.2020.01.002_bib34","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.iac.2016.08.007","article-title":"Itch in atopic dermatitis","volume":"37","author":"Kido-Nakahara","year":"2017","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1016\/j.alit.2020.01.002_bib35","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.cell.2017.08.006","article-title":"Sensory neurons co-opt classical immune signaling pathways to mediate chronic itch","volume":"171","author":"Oetjen","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.alit.2020.01.002_bib36","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1248\/bpb.b13-00319","article-title":"An update on peripheral mechanisms and treatments of itch","volume":"36","author":"Tominaga","year":"2013","journal-title":"Biol Pharm Bull"},{"key":"10.1016\/j.alit.2020.01.002_bib37","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1056\/NEJMoa1314768","article-title":"Dupilumab treatment in adults with moderate-to-severe atopic dermatitis","volume":"371","author":"Beck","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.alit.2020.01.002_bib38","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa1610020","article-title":"Two phase 3 trials of dupilumab versus placebo in atopic dermatitis","volume":"375","author":"Simpson","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.alit.2020.01.002_bib39","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1016\/S0140-6736(17)31191-1","article-title":"Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial","volume":"389","author":"Blauvelt","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.alit.2020.01.002_bib40","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jaad.2019.07.074","article-title":"Dupilumab shows long-term safety and efficacy in moderate-to-severe atopic dermatitis patients enrolled in a phase 3 open-label extension study","volume":"82","author":"Deleuran","year":"2020","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.alit.2020.01.002_bib41","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1111\/bjd.17869","article-title":"Conjunctivitis in dupilumab clinical trials","volume":"181","author":"Akinlade","year":"2019","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.alit.2020.01.002_bib42","article-title":"Real-life practice: rapid improvement in itch symptomatology in patients with atopic dermatitis treated with dupilumab","author":"Pistone","year":"2019","journal-title":"J\u00a0Dermatolog Treat"},{"key":"10.1016\/j.alit.2020.01.002_bib43","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1111\/bjd.16156","volume":"178","author":"de Bruin-Weller","year":"2018","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.alit.2020.01.002_bib44","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/S0140-6736(17)33311-1","article-title":"Asthma","volume":"391","author":"Papi","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.alit.2020.01.002_bib45","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1183\/09031936.00202013","article-title":"International ERS\/ATS guidelines on definition, evaluation and treatment of severe asthma","volume":"43","author":"Chung","year":"2014","journal-title":"Eur Respir J"},{"key":"10.1016\/j.alit.2020.01.002_bib46","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.alit.2019.06.003","article-title":"Prevalence, disease burden, and treatment reality of patients with severe, uncontrolled asthma in Japan","volume":"69","author":"Nagase","year":"2020","journal-title":"Allergol Int"},{"key":"10.1016\/j.alit.2020.01.002_bib47","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1159\/000338998","article-title":"The cost of persistent asthma in Europe: an international population-based study in adults","volume":"160","author":"Accordini","year":"2013","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.alit.2020.01.002_bib48","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.anai.2015.03.019","article-title":"Outcomes before and after treatment escalation to Global Initiative for Asthma steps 4 and 5 in severe asthma","volume":"114","author":"Sullivan","year":"2015","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.alit.2020.01.002_bib49","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1016\/S0140-6736(15)00157-9","article-title":"Targeting the interleukin pathway in the treatment of asthma","volume":"386","author":"Chung","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.alit.2020.01.002_bib50","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s11882-013-0373-9","article-title":"Role of interleukin-13 in asthma","volume":"13","author":"Corren","year":"2013","journal-title":"Curr Allergy Asthma Rep"},{"key":"10.1016\/j.alit.2020.01.002_bib51","doi-asserted-by":"crossref","first-page":"3546","DOI":"10.1172\/JCI36130","article-title":"The cytokine network in asthma and chronic obstructive pulmonary disease","volume":"118","author":"Barnes","year":"2008","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.alit.2020.01.002_bib52","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1172\/JCI84910","article-title":"Epithelial tethering of MUC5AC-rich mucus impairs mucociliary transport in asthma","volume":"126","author":"Bonser","year":"2016","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.alit.2020.01.002_bib53","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/nri2735","article-title":"How are TH2-type immune responses initiated and amplified?","volume":"10","author":"Paul","year":"2010","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.alit.2020.01.002_bib54","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/nrd4624","article-title":"Targeting key proximal drivers of type 2 inflammation in disease","volume":"15","author":"Gandhi","year":"2016","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.alit.2020.01.002_bib55","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.jaci.2006.02.046","article-title":"Periostin: a novel component of subepithelial fibrosis of bronchial asthma downstream of IL-4 and IL-13 signals","volume":"118","author":"Takayama","year":"2006","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.alit.2020.01.002_bib56","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1304048","article-title":"Dupilumab in persistent asthma with elevated eosinophil levels","volume":"368","author":"Wenzel","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.alit.2020.01.002_bib57","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(16)30307-5","article-title":"Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting \u03b22 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial","volume":"388","author":"Wenzel","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.alit.2020.01.002_bib58","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1056\/NEJMoa1804092","article-title":"Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma","volume":"378","author":"Castro","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.alit.2020.01.002_bib59","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1056\/NEJMoa1804093","article-title":"Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma","volume":"378","author":"Rabe","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.alit.2020.01.002_bib60","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1172\/JCI95693","article-title":"Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction","volume":"128","author":"Dunican","year":"2018","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.alit.2020.01.002_bib61","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1016\/j.chest.2019.02.403","article-title":"CT and functional MRI to evaluate airway mucus in severe asthma","volume":"155","author":"Svenningsen","year":"2019","journal-title":"Chest"},{"key":"10.1016\/j.alit.2020.01.002_bib62","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1136\/thoraxjnl-2019-213415","article-title":"Normalisation of MRI ventilation heterogeneity in severe asthma by dupilumab","volume":"74","author":"Svenningsen","year":"2019","journal-title":"Thorax"},{"key":"10.1016\/j.alit.2020.01.002_bib63","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/resp.13419_69","article-title":"The prevalence and clinical characteristics of T2-low and T2-high endotype of severe uncontrolled asthma distinguished by combining type-2 biomarkers","volume":"23","author":"Oishi","year":"2018","journal-title":"Respirology"},{"key":"10.1016\/j.alit.2020.01.002_bib64","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.jaip.2017.06.015","article-title":"Subphenotypes of type 2 severe asthma in adults","volume":"6","author":"Matsusaka","year":"2018","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.alit.2020.01.002_bib65","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1177\/194589240401800307","article-title":"Histopathological features of nasal polyps with asthma association: an immunohistochemical study","volume":"18","author":"Haruna","year":"2004","journal-title":"Am J Rhinol"},{"key":"10.1016\/j.alit.2020.01.002_bib66","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1111\/all.12644","article-title":"Novel scoring system and algorithm for classifying chronic rhinosinusitis: the JESREC Study","volume":"70","author":"Tokunaga","year":"2015","journal-title":"Allergy"},{"key":"10.1016\/j.alit.2020.01.002_bib67","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1016\/j.jaip.2017.04.024","article-title":"Biotherapeutics in chronic rhinosinusitis with and without nasal polyps","volume":"5","author":"Bachert","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.alit.2020.01.002_bib68","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.alit.2019.07.002","article-title":"Eosinophilic chronic rhinosinusitis","volume":"68","author":"Fujieda","year":"2019","journal-title":"Allergol Int"},{"key":"10.1016\/j.alit.2020.01.002_bib69","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1016\/j.jaci.2016.09.008","article-title":"Advances in rhinitis and rhinosinusitis in 2015","volume":"138","author":"Bachert","year":"2016","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.alit.2020.01.002_bib70","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1165\/rcmb.2017-0325OC","article-title":"Expression and functional analysis of CST1 in intractable nasal polyps","volume":"59","author":"Kato","year":"2018","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1016\/j.alit.2020.01.002_bib71","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1164\/rccm.201207-1292OC","article-title":"Excessive fibrin deposition in nasal polyps caused by fibrinolytic impairment through reduction of tissue plasminogen activator expression","volume":"187","author":"Takabayashi","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.alit.2020.01.002_bib72","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1016\/S0140-6736(19)31881-1","article-title":"Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials","volume":"394","author":"Bachert","year":"2019","journal-title":"Lancet"}],"container-title":["Allergology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1323893020300083?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1323893020300083?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T18:09:38Z","timestamp":1761156578000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1323893020300083"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":72,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["S1323893020300083"],"URL":"https:\/\/doi.org\/10.1016\/j.alit.2020.01.002","relation":{},"ISSN":["1323-8930"],"issn-type":[{"value":"1323-8930","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dupilumab: Basic aspects and applications to allergic diseases","name":"articletitle","label":"Article Title"},{"value":"Allergology International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.alit.2020.01.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Japanese Society of Allergology. Production and hosting by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}